Antibody-mediated growth inhibition of Plasmodium falciparum: Relationship to age and protection from parasitemia in Kenyan children and adults

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Dent, Arlene E ^a   Bergmann Leitner, Elke S ^b   Wilson, Danny W ^c,d   Tisch, Daniel J ^a   Kimmel, Rhonda ^a   Vulule, John ^e   Sumba, Peter Odada ^e   Beeson, James G ^c   Angov, Evelina ^b   Moormann, Ann M ^a   Kazura, James W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

PARASITE ANTIBODY; GROWTH INHIBITOR; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SMEAR; CHILD; CONTROLLED STUDY; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INFECTION RESISTANCE; INFECTION RISK; KENYA; NORMAL HUMAN; PARASITE DEVELOPMENT; PARASITE IMMUNITY; PARASITEMIA; PLASMODIUM FALCIPARUM; AGE; ANIMAL; BLOOD; CELL CULTURE; EPIDEMIOLOGY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIFE CYCLE; MALARIA FALCIPARUM; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; TIME;

PLASMODIUM FALCIPARUM;

ADULT; AGE FACTORS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; GROWTH INHIBITORS; HUMANS; KENYA; LIFE CYCLE STAGES; MALARIA, FALCIPARUM; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS;

EID: 55849149780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003557     Document Type: Article

References (64)

1. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, et al. (1994) The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51: 123-137.
2. Cohen S, Mc GI, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
3. McGregor IA (1964) The Passive Transfer of Human Malarial Immunity. Am J Trop Med Hyg 13: SUPPL 237-239.
4. Marsh K, Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite Immunol 28: 51-60.
5. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
6. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
7. Berendt AR, Ferguson DJ, Gardner J, Turner G, Rowe A, et al. (1994) Molecular mechanisms of sequestration in malaria. Parasitology 108 Suppl: S19-28.
8. Bull PC, Lowe BS, Kaleli N, Njuga F, Kortok M, et al. (2002) Plasmodium falciparum infections are associated with agglutinating antibodies to parasite-infected erythrocyte surface antigens among healthy Kenyan children. J Infect Dis 185: 1688-1691.
9. Newbold CI, Craig AG, Kyes S, Berendt AR, Snow RW, et al. (1997) PfEMP1, polymorphism and pathogenesis. Ann Trop Med Parasitol 91: 551-557.
10. Eisen DP, Wang L, Jouin H, Murhandarwati EE, Black CG, et al. (2007) Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals. Malar J 6: 86.
11. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, et al. (2006) Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24: 3009-3017.
12. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, et al. (2007) Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25: 4203-4212.
13. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, et al. (2006) Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children. PLoS Clin Trials 1: e32.
14. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, et al. (1998) A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 58: 211-219.
15. Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, et al. (2004) Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun 72: 6492-6502.
16. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, et al. (2003) Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 25: 307-312.
17. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, et al. (2005) Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 191: 264-271.
18. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
19. Polley SD, Tetteh KK, Cavanagh DR, Pearce RJ, Lloyd JM, et al. (2003) Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun 71: 1833-1842.
20. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ, Greenwood BM, et al. (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 195: 279-287.
21. Yone CL, Kremsner PG, Luty AJ (2005) Immunoglobulin G isotype responses to erythrocyte surface-expressed variant antigens of Plasmodium falciparum predict protection from malaria in African children. Infect Immun 73: 2281-2287.
22. Mackintosh CL, Mwangi T, Kinyanjui SM, Mosobo M, Pinches R, et al. (2008) Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J Parasitol 38: 1445-1454.
23. Good MF (2005) Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol 26: 295-297.
24. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, et al. (2005) The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 73: 287-297.
25. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, et al. (2003) Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 71: 6766-6774.
26. Singh S, Miura K, Zhou H, Muratova O, Keegan B, et al. (2006) Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74: 4573-4580.
27. Bolad A, Nebie I, Cuzin-Ouattara N, Traore A, Esposito F, et al. (2003) Antibody-mediated in vitro growth inhibition of field isolates of Plasmodium falciparum from asymptomatic children in Burkina Faso. Am J Trop Med Hyg 68: 728-733.
28. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, et al. (2007) Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE 2: e1045.
29. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, et al. (2006) Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 1: e34.
30. Makler MT, Hinrichs DJ (1993) Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg 48: 205-210.
31. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E (2008) Miniaturization of a High-throughput pLDH-based Plasmodium falciparum Growth Inhibition Assay for Small Volume Samples from Preclinical and Clinical Vaccine Trials. Am J Trop Med Hyg 78: 468-471.
32. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, et al. (2006) Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 75: 437-442.
33. Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA (1999) Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 60: 135-141.
34. Persson KE, Lee CT, Marsh K, Beeson JG (2006) Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44: 1665-1673.
35. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, et al. (1999) Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 60: 641-648.
36. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC, et al. (2004) Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 72: 5135-5142.
37. O'Donnell RA, Saul A, Cowman AF, Crabb BS (2000) Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. Nat Med 6: 91-95.
38. Grimberg BT, Erickson JJ, Sramkoski RM, Jacobberger JW, Zimmerman PA (2008) Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst-thiazole orange staining strategy. Cytometry A.
39. Jacobberger JW, Horan PK, Hare JD (1992) Cell cycle analysis of asexual stages of erythrocytic malaria parasites. Cell Prolif 25: 431-445.
40. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, et al. (2008) Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 118: 342-351.
41. Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, et al. (2007) Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother 51: 1926-1933.
42. Sy NE, Oberst RB, Macalagay PS, Fallarme VD, Cruzada SF, et al. (1990) In vitro growth inhibition of Plasmodium falciparum by sera from different regions of the Philippines. Am J Trop Med Hyg 43: 243-247.
43. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
44. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310.
45. Caceres VM, Strebel PM, Sutter RW (2000) Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 31: 110-119.
46. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, et al. (2004) Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173: 666-672.
47. Chookajorn T, Dzikowski R, Frank M, Li F, Jiwani AZ, et al. (2007) Epigenetic memory at malaria virulence genes. Proc Natl Acad Sci U S A 104: 899-902.
48. Iyer JK, Amaladoss A, Genesan S, Preiser PR (2007) Variable expression of the 235 kDa rhoptry protein of Plasmodium yoelii mediate host cell adaptation and immune evasion. Mol Microbiol 65: 333-346.
49. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, et al. (2005) Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 309: 1384-1387.
50. Mlambo G, Kumar N (2007) A modified Plasmodium falciparum growth inhibition assay (GIA) to assess activity of plasma from malaria endemic areas. Exp Parasitol 115: 211-214.
51. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, et al. (2007) Longterm clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 4: e320.
52. Sarr JB, Remoue F, Samb B, Dia I, Guindo S, et al. (2007) Evaluation of antibody response to Plasmodium falciparum in children according to exposure of Anopheles gambiae s.1 or Anopheles funestus vectors. Malar J 6: 117.
53. Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, et al. (2006) High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am J Trop Med Hyg 74: 191-197.
54. Omosun YO, Anumudu CI, Adoro S, Odaibo AB, Sodeinde O, et al. (2005) Variation in the relationship between anti-MSP-1(19) antibody response and age in children infected with Plasmodium falciparum during the dry and rainy seasons. Acta Trop 95: 233-247.
55. Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, et al. (2005) Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 73: 422-430.
56. Chelimo K, Ofulla AV, Narum DL, Kazura JW, Lanar DE, et al. (2005) Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya. Pediatr Infect Dis J 24: 680-684.
57. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, et al. (2000) Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620.
58. Dent A, Malhotra I, Mungai P, Muchiri E, Crabb BS, et al. (2006) Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J Immunol 177: 7139-7145.
59. McCallum FJ, Persson KE, Mugyenji CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG (2008) Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoSOne (in press).
60. Druilhe P, Perignon JL (1994) Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol Lett 41: 115-120.
61. Miller LH, Hoffman SL (1998) Research toward vaccines against malaria. Nat Med 4: 520-524.
62. Mu J, Awadalla P, Duan J, McGee KM, Keebler J, et al. (2007) Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet 39: 126-130.
63. Flyg BW, Perlmann H, Perlmann P, Esposito F, Berzins K (1997) Wild isolates of Plasmodium falciparum malaria show decreased sensitivity to in vitro inhibition of parasite growth mediated by autologous host antibodies. Clin Exp Immunol 107: 321-327.
64. Malkin E, Long CA, Stowers AW, Zou L, Singh S, et al. (2007) Phase 1 Study of Two Merozoite Surface Protein 1 (MSP1(42)) Vaccines for Plasmodium falciparum Malaria. PLoS Clin Trials 2: e12.